No significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms, study shows
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms. The trial was stopped in February 2021 due to lack of efficacy based on a planned interim analysis.
from Top Health News -- ScienceDaily https://ift.tt/37Tv5ip
from Top Health News -- ScienceDaily https://ift.tt/37Tv5ip
Comments
Post a Comment